SEARCH

SEARCH BY CITATION

Keywords:

  • meta-analysis;
  • hemoglobin;
  • anemia;
  • cancer;
  • survival;
  • mortality;
  • prognostic factors;
  • death;
  • prognosis

Abstract

  1. Top of page
  2. Abstract
  3. MATERIALS AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. REFERENCES

BACKGROUND

Anemia is common in cancer patients, although the prevalence is influenced both by the type of malignancy and the choice of treatment. Individual studies have compared the survival of patients with and without anemia and have shown reduced survival times in patients with various malignancies, including carcinoma of the lung, cervix, head and neck, prostate, lymphoma, and multiple myeloma. The objective of this study was to systematically review, to summarize, and to obtain an overall estimate of the effect of anemia on survival in patients with malignant disease.

METHODS

A comprehensive literature review was carried out using the MEDLINE data base and reviewing the reference lists from published studies. Two hundred papers were identified. Of these, 60 papers that reported the survival of cancer patients according to either hemoglobin levels or the presence of anemia were included. Among these papers, 25% related to patients with lung carcinoma, 17% related to patients with head and neck carcinoma, 12% related to patients with multiple myeloma, 10% related to patients with prostate carcinoma, 8% related to patients with cervicouterine carcinoma, 7% related to patients with leukemia, 5% related to patients with lymphoma, and 16% related to patients with other types of malignancies.

RESULTS

The relative risk of death increased by 19% (95% confidence interval, 10–29%) in anemic patients with lung carcinoma, by 75% (37–123%) in anemic patients with head and neck carcinoma, by 47% (21–78%) in anemic patients with prostate carcinoma, and by 67% (30–113%) in anemic patients with lymphoma. The overall estimate increase in risk was 65% (54–77%).

CONCLUSIONS

Anemia is associated with shorter survival times for patients with lung carcinoma, cervicouterine carcinoma, head and neck carcinoma, prostate carcinoma, lymphoma, and multiple myeloma. Cancer 2001;91:2214–21. © 2001 American Cancer Society.

Anemia is a common finding in cancer patients.1 Up to 30% of patients with tumors have been reported to suffer from anemia.2 This can be related to the disease process itself or to its treatment, whether it is chemotherapy or radiotherapy. The factors associated with anemia itself encompass disorders of iron metabolism,3 reduced numbers of erythroid progenitor cells in the bone marrow, increased levels of inflammatory cytokines,4 extracorpuscular hemolysis, catabolism of patients with tumor burden, and relative deficiency of erythropoietin.2

Generally, the anemia is considered within the category of anemia of chronic diseases as normocytic and normochromic.3 The association of increased hemoglobin levels with increased quality of life has been demonstrated by randomized, controlled trials and large, community-based studies.5–8 Some authors have suggested that maintenance of hemoglobin levels may improve survival, mainly in patients with extensive spread of disease.

Some authors have suggested that the maintenance of hemoglobin at normal levels would improve the quality of life9, 10 and survival, mainly in patients with extensive spread of disease.4 Individual studies have compared the survival of patients with and without anemia and have found reduced survival times in patients with a wide range of malignancies, including those of the lung, cervix, head and neck, and prostate; lymphoma; and multiple myeloma. Despite the number of individual studies addressing the topic, no quantitative, comprehensive review has been published examining the correlation between anemia and survival in cancer patients and no overall estimate has been published.

MATERIALS AND METHODS

  1. Top of page
  2. Abstract
  3. MATERIALS AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. REFERENCES

Study Identification

Two researchers independently searched the MEDLINE data base using the keywords hemoglobin, hematocrit, and anemia and survival, prognosis, survival rates, survival, hazard, death, mortality, hazard rate ratio, Cox proportional hazard and cancer, neoplasia, and oncology in various types of malignancies. The search was carried back 30 years without any language limitations. The references from all reviews or original papers also were searched to complete the list of potential papers for assessment.

Study Eligibility

The two researchers also independently reviewed the list of articles for potential inclusion. All disagreements were then resolved by consensus. The decision to include an article was not related to the study's results. The articles selected met the following inclusion criteria: diagnosis of cancer and survival data stratified by hemoglobin levels or anemia or otherwise reported in a manner that permitted the results to be examined in this way. Also, articles that did not report the total number or proportion of anemic patients were excluded. All studies that were reported only as abstracts were excluded from the analyses.

Data Extraction

Studies were reviewed independently by the two investigators, and any differences were resolved by consensus. Information was retrieved on study design, patient age, gender, types of malignancy, hemoglobin levels, hematocrit levels and/or anemia, survival times or rates at particular intervals or overall, hazard rates, rate ratios (unadjusted and adjusted estimates with their corresponding variables), and confounding or modifier variables, such as disease severity, treatment, and blood transfusions. We accepted the primary study authors' definitions for each malignancy.

Statistical Analysis

All data were entered into an electronic data base for the statistical analyses. Because the studies reported survival in different ways, we transformed cumulative survival over a given period to hazard rates using

  • equation image

where λ is the hazard over the period, and S(t) is the survival (or 1 − M(t); the mortality) over time t. To transform the median survival to hazard, a constant hazard over time was assumed.

We calculated the hazard rate ratio (HRR; hazard with anemia and/or hazard without anemia) for each study. The analysis of HRR was carried out according to the information available. If the authors reported HRR obtained from a univariate analysis (or if we calculated the HRR from survival estimates) that did not consider other factors, then these estimates were labeled unadjusted HRRs (uHRRs). If the authors reported an HRR in light of other factors (using a Cox proportional hazards model) or reported a β coefficient for anemia to derive the HRR, then these estimates were considered adjusted HRRs (aHRRs). The aHRRs were extracted from articles irrespective of the prognostic factors for each malignancy.

For the uHRR, the hazard rates were pooled using the proportion of the total number of patients as the weight for each study. Because the articles did not consistently report any measure of variation, we could not estimate the confidence intervals of unadjusted estimates. To reduce the heterogeneity among studies, we stratified by disease, although it was not possible to stratify by severity because of insufficient data.

To estimate the aHRR and corresponding 95% confidence interval (95% CI) by study, we used the published information of β coefficient and standard error. In this case, it was possible to use the inverse of the variance as source of weights to pool the aHRR. The 95% CI for the overall aHRR (âHRR) was calculated using

  • equation image

where weights are given by the inverse of the variance.11, 12

To assess the possibility of publication bias, the uHRRs were plotted against the sample size (inverted funnel plot) and the year of publication. Also, a cumulative meta-analysis, a type of meta-analysis in which the combined point estimate of an effect is computed sequentially by adding one study at a time in a prespecified order,13, 14 was done by type of disease.

RESULTS

  1. Top of page
  2. Abstract
  3. MATERIALS AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. REFERENCES

Two hundred articles were identified, with the majority published in English. We excluded 30 reviews, 108 articles with insufficient data (no hemoglobin data or no survival data), and 2 articles that reported only disease free survival.2 Sixty studies were included, and, among them, two Japanese,15, 16 one Chinese,17 one Polish,18 and one French study met the inclusion criteria.19 Twenty-five percent of the studies focused on patients with carcinoma of the lung, 17% focused on patients with carcinoma of the head and neck, 12% focused on patients with multiple myeloma, 10% focused on patients with prostate carcinoma, 8% focused on patients with cervicouterine carcinoma, 7% focused on patients with leukemia, 5% focused on patients with lymphoma, and 16% focused on patients with other malignancies (Table 1).

Table 1. Distribution of Studies, Pooled Unadjusted and Adjusted Hazard Rate Ratios, and 95% Confidence Intervals by Disease Type
Type of diseaseReference(s)No. of studies (%)Unadjusted HRRAdjusted HRR (95% CI)
  1. HRR: hazard rate ratio; NR: not reported.

Lung15–17, 21–3215 (25.0)1.541.19 (1.10–1.29)
Head and neck carcinoma18, 33–4110 (17.0)2.351.75 (1.37–2.23)
Multiple myeloma19, 42–477 (12.0)4.47NR
Prostate carcinoma48–536 (10.0)1.781.47 (1.21–1.78)
Cervicouterine carcinoma20, 54–575 (8.0)2.61NR
Leukemia58–614 (7.0)2.11NR
Lymphoma62–643 (5.0)3.741.67 (1.30–2.13)
Renal carcinoma652 (3.0)1.90NR
Ovarian carcinoma1, 662 (3.0)1.40NR
Colorectal carcinoma67, 682 (3.0)1.83NR
Other69–724 (7.0)1.47–1.59NR
Total60 (100.0)Overall, 2.33Overall, 1.65 (1.54–1.77)

In relation to the study type, we found 39 cohort studies, 19 randomized clinical trials, and 2 case-referent studies. The majority of the participants were receiving current chemotherapy and/or radiotherapy treatment at the time that the hemoglobin or anemia status was established. Generally, the authors did not report whether a patient received transfusion.

A key issue was the criteria used by the authors to diagnose anemia. Some authors reported only anemia versus no anemia without providing the criteria used, others stratified by hemoglobin levels, and the cut-off point varied from 8.5 g/dL to 14.0 g/dL. Some authors used different hemoglobin cut-off points for male patients and female patients but did not include the gender distribution in the article.

The median survival time varied according to the disease as well as the presence of anemia. For patients with anemia, the median survival ranged from 4 months (lung carcinoma and multiple myeloma) to 96 months (prostate carcinoma) compared with 7 months (lung carcinoma) to 120 months (prostate carcinoma) for patients who were not anemic. In all studies, the median survival was longer for patients without anemia compared with the anemic patients (Fig. 1).

thumbnail image

Figure 1. Median survival times (in months) for patients with and without anemia.

Download figure to PowerPoint

When the uHRR was calculated for each study, we found that it varied according to the disease, but it was always higher for patients with anemia, regardless of the type of malignancy. For example, the uHRR ranged from 1.2 to 2.6 in lung carcinoma studies, from 1.3 to 1.4 in ovarian carcinoma studies, and from 1.5 to 9.0 in multiple myeloma studies. For some types of malignancies, like multiple myeloma and lymphoma, the average uHRR was > 5. It is possible that this reflects the involvement of bone marrow and other reticuloendothelial sites in these diseases. Another possibility may be that it reflects disease severity; however, because the articles did not report a correlation between anemia and survival by disease severity, we could not examine this possibility. We pooled all unadjusted hazard rates to obtain the overall uHRR by disease weighted by sample size (Table 1).

For the studies that reported the aHRR obtained from a Cox proportional hazards multivariate model or the corresponding β coefficient, we also compared the aHRR and 95% CI by disease. The aHRRs were significantly > 1.0 in the majority of the studies, ranging from 1.1 to 2.5 for the individual studies. Some studies had wide 95% CI levels because of the small number of participants in the study. The overall aHRR and 95% CI was estimated for diseases that were reported in more than one study, and they were statistically significant for all four of the diseases studied: lung carcinoma, head and neck carcinoma, prostate carcinoma, and lymphoma. The overall aHRR was 1.65 with a 95% CI of 1.54–1.77 (Table 1).

The cumulative HRRs showed a positive relation between anemia and survival by type of disease. The cumulative HRRs ranged between 3.18 for lymphoma and 7.04 for lung carcinoma.

Publication Bias

The estimates also were plotted against sample size to observe the effect on the distribution of the HRR estimates (inverted funnel plot) (Fig. 2). There were no differences between small studies and large studies in relation to either the uHRR or the aHRR. There was no evidence of positive publication bias, because the smaller studies were not skewed toward a higher HRR estimate and covered a wider range of values than the larger studies.

thumbnail image

Figure 2. Funnel plot of unadjusted hazard rate ratio versus sample size to explore publication bias.

Download figure to PowerPoint

The aHRR estimates were published only for models in which anemia was a significant predictor. Nevertheless, because the main objective of the majority of papers was not related to the anemia-survival relation, publication bias may not have arisen for the articles that reported aHRR. In addition, the uHRRs were estimated for 39 studies, and these also showed no evidence of a substantial publication bias.

DISCUSSION

  1. Top of page
  2. Abstract
  3. MATERIALS AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. REFERENCES

Anemia is common in cancer patients,1, 20 and it has been associated with lower survival. In our study, ≈33% of patients were diagnosed as anemic, and the median survival was reduced by 20–43%. Individual studies have reported this association in patients with a variety of diseases. Therefore, this meta-analysis was carried out to combine the survival information from individual studies to get an overall estimate of the association between survival and anemia.

From the 60 articles that were included, the majority reported median survival, and 21 articles (35%) published the impact of anemia on survival adjusted for other factors, such as clinical stage and performance status. The type of disease did influence survival time; therefore, the results were reported separately for each type of malignancy.

In the current study, we found that anemic patients, compared with nonanemic patients, with carcinoma of the lung, prostate, and head and neck as well as lymphoma had a significant reduction in survival. The association remains significant even after adjusting for other factors. For example, there is a 19% greater risk of death if a patient with carcinoma of the lung has anemia (95% CI, 1.10–1.29). Is the anemia an independent predictor of survival, regardless of disease severity, or does it modify the relation between disease severity and survival? Anemia may be an independent predictor of survival, because the published Cox proportional hazards models were adjusted for disease stage and/or severity. This strongly implies that anemia is an independent predictor of survival. In this meta-analysis, however, it was not possible to determine whether anemia modifies the relation between disease severity and survival.

The aHRR, although it still was significantly greater than 1.0, was less than the unadjusted rate, suggesting that some of the effect was due to imbalances in other factors. Nevertheless, some of the regression models used to control for other factors included variables like performance status that actually may reflect the anemic status. If this is true, then the models are partitioning the effect of anemia into two variables, thus underestimating the true HRR.

The small number of studies addressing this topic for each type of malignancy is the major limitation of this meta-analysis. We included both randomized clinical trials and observational studies. The randomized clinical trials were not designed primarily to examine the effect of anemia, but they retrospectively analyzed the prognostic factors in patients with cancer. The observational studies were mostly of the cohort design, but there were two case-referent studies, a design commonly used to study prognosis in the oncology setting.

The criteria used to classify a patient as anemic varied between individual studies. For this meta-analysis, hemoglobin levels < 8.5–14.0 g/dL were used as well as a requirement for transfusion to classify patients as anemic. Therefore, this analysis pools the impact across a range of hemoglobin levels. The information in the reports was too limited to analyze the relation between different hemoglobin levels and survival.

Most of the studies were observational; therefore, a certain degree of heterogeneity among populations and study design may have influenced the results. One limitation of the unadjusted hazard rate estimates was that they were derived from median survival times assuming a constant hazard. Another issue related to our results may have been publication bias, because the majority of authors who reported on anemia in the aHRR for anemic patients did so because it was a statistically significant factor. We explored this possibility by estimating the uHRR for each study and pooling by type of disease, with results and direction similar to those in the aHRR. Also, we plotted both aHRR and uHRR by year of publication and sample size without any clear evidence of publication bias. The potential mechanisms accounting for this reduction in survival are multiple and include reduced free radical formation in the tumor leading to radioresistance and modification of hypoxia-inducible genes (e.g., vascular endothelial growth factor, p53, HIF-1, etc.).

One limitation of this study is that it was not possible to determine whether anemia is the cause of decreased survival or a surrogate for other adverse factors. It is possible that anemia may be due to direct interference by the malignancy in red blood cell production, like what is seen in patients with multiple myeloma or lymphoma. Alternatively, it may be an indirect effect of high tumor burden and/or biologic effects, for example, through cytokine interference with red blood cell production. Furthermore, patients were receiving chemotherapy or radiotherapy; therefore, it is difficult to implicate anemia as a direct cause of decreased survival. However, from this study, it was clear that patients with anemia–as either a direct cause or an indirect cause–have lower survival.

Given the serious reduction in patient survival implied by anemia, it appears that the potential impact of its correction should be considered strongly by clinicians, although which treatment to employ for anemic patients is not obvious. An apparent choice is transfusion, but this presents problems, such as availability of blood, risk of infections, cost, and (very important for some patients) a poor prognosis in and of itself. Another treatment option that has become available recently for anemic patients with malignancies is recombinant human erythropoietin.

In conclusion, this study showed that anemia is a strong predictor of poorer survival in cancer patients. Although additional studies are necessary to determine whether treating anemia improves survival, its impact should be considered when planning and analyzing the impact of novel treatments for patients with malignant disease.

REFERENCES

  1. Top of page
  2. Abstract
  3. MATERIALS AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. REFERENCES
  • 1
    Obermair A, Handisurya A, Kaider A, Sevelda P, Kolbl H, Gitsch G. The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients. Cancer 1998; 83: 72631.
  • 2
    Tesarova P, Kvasnicka J. Erythropoietin therapy in cancer patients. Cas Leuk Ces 1995; 20: 64750.
  • 3
    DeRienzo DP, Saleem A. Anaemia of chronic disease: a review of pathogenesis. Texas Med 1990; 86: 803.
  • 4
    Ludwig H, Fritz E. Anemia in cancer patients. Semin Oncol 1998; 25(Suppl 7): 26.
  • 5
    Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer 1993; 29A(Suppl 2): S28.
  • 6
    Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alpha on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997; 15(3): 121834.
  • 7
    Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alpha is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998; 16: 341225.
  • 8
    Gabrilove JL, Einhorn LH, Livinston RB, Winer E, Cleeland CS. Once-weekly dosing of epoetin alpha is similar to three times weekly dosing in increasing hemoglobin and quality of life. Proc Am Soc Clin Oncol 1999; 18: 574A.
  • 9
    Manegold C. The causes and prognostic significance of low hemoglobin levels in tumor patients. Strahlenther Onkol 1998; 174(Suppl IV): 179.
  • 10
    Ludwig H, Fritz E. Anemia of cancer patients: patient selection and patient stratification for epoetin treatment. Semin Oncol 1998; 25(Suppl 7): 358.
  • 11
    Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res 1993; 2: 12145.
  • 12
    Kleinbaum DG, Kupper LL, Morgenstern H. Point estimation of overall effect and interval estimation of effect. In: KleinbaumDG, KupperLL, MorgensternH, editors. Epidemiologic research. Principles and quantitative methods, 1st edition. New York: Van Nostrand Reinhold, 1982: 34076.
  • 13
    Lau J, Schmid CH, Chalmers TC. Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. J Clin Epidemiol 1995; 48: 4557.
  • 14
    Lau J, Antman EM, Jimenez-Silva J, et al. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992; 327: 24854.
  • 15
    Takifuji N, Fukuoka M, Negoro S, Takada M, Kusonoki Y, Matsui K, et al. Prognostic factors affecting survival and response in patients with advanced non-small cell lung cancer treated with combination chemotherapy. Gan To Kagaku Ryoho 1990; 17( 3 Pt 2): 42934.
  • 16
    Sekiguchi K, Yamashita T, Hayashi S, Aoki M, Kitahara T, Sekine H, et al. Prognostic factors of radiation therapy for patients with nonoperative Stage III non-small cell lung cancer. Nippon Igaku Hoshasen Gakkai Zasshi 1994; 54(10): 9991006.
  • 17
    Ding SL, Ger LP, Kao SJ, Shen CY. Small cell-lung cancer: survival analysis of 96 cases. Chung Hua I Hsueh Tsa Chih 1989; 43 (3): 197204.
  • 18
    Skladowski K, Zajusz A, Swiatnicka J, Maciejewska M, Krupska T, Majewski S, et al. Prognostic factors in radiotherapy of supraglottic cancer. Otolaryngol Pol 1996; 50(6): 57986.
  • 19
    Zakraoui L, Cheour I, Jeridi T, Jellouli N, Bergaoui N, Moalla M, et al. Prognostic factors in multiple myeloma. Critical analysis based on a multicenter study of 53 cases. Tunis Med 1988;66(10): 66372.
  • 20
    Grogan M, Thomas GM, Melamed I, Wong FLW, Pearcey RG, Joseph PK, et al. The importance of maintaining high hemoglobin levels during radiation treatment of carcinoma of the cervix. Cancer 1999; 86: 152836.
  • 21
    Sorensen JB, Badsberg JH, Olsen J. Prognostic factors in inoperable adenocarcinoma of the lung. Cancer Res 1989; 49: 574854.
  • 22
    Ohlhauser C, Bulzebruck H, Ebert W, Drings P, Wannenmacher M. Prognostic factors for survival in inoperable non-small-cell lung cancer. A multivariate regression analysis of 456 patients with radiation therapy. Oncology 1997;20: 12631.
  • 23
    Cohen MH, Makuch R, Johnston-Early A, Ihde DC, Bunn PA, Fossieck BE, et al. Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer. Cancer Treat Rep 1981; 65: 18795.
  • 24
    Yamamoto N, Tamura T, Fukuoka M. Survival and prognostic factors in lung cancer patients treated in Phase I trials: Japanese experience. Int J Oncol 1999; 15: 73741.
  • 25
    Sorensen JB, Badsberg JH. Prognostic factors in resected Stages I and II adenocarcinoma of the lung. A multivariate regression analysis of 137 consecutive patients. J Thorac Cardiovasc Surg 1990;99(2): 218-26.
  • 26
    Osterlind K, Andersen PK. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res 1986; 46(8): 418994.
  • 27
    Tamura M, Ueoka H, Kiura K, Tabata M, Shibayama T, Miyatake K, et al. Prognostic factors of small-cell lung cancer in Okayama Lung Cancer Study Group trials. Acta Med Okayama 1998; 52(2): 10511.
  • 28
    Souhami RL, Bradbury I, Geddes DM, Spiro SG, Harper PG, Tobias JS. Prognostic significance of laboratory parameters measured at prognosis in small cell carcinoma of the lung. Cancer Res 1985; 45: 287882.
  • 29
    Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Kojima A, et al. A prognostic factor risk index in advanced non small cell lung cancer treated with cisplatin containing combination chemotherapy. Cancer Chemother Pharmacol 1992; 30: 16.
  • 30
    Gail MH, Eagan RT, Feld R, Ginsberg R, Goodell B, Hill L, et al. Prognostic factors in patients with resected stage non-small cell lung cancer. Cancer 1984; 54: 180213.
  • 31
    Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991; 9: 161826.
  • 32
    Okamoto H, Saijo N, Shinkai T, Eguchi K, Sasaki Y, Tamura T, et al. Chemotherapy-induced anemia in patients with primary lung cancer. Ann Oncol 1992; 3(10): 81924.
  • 33
    Frommheld H, Guttenberger R, Henke M. The impact of blood hemoglobin content on the outcome of radiotherapy. Strahlenther Onkol 1998; 174(Suppl IV): 314.
  • 34
    Bryne M, Eide GE, Lilleng R, Langmark F, Thrane PS, Dabelsteen E. A multivariate analysis of the prognosis of oral squamous cell carcinoma. Cancer 1991; 68: 19948.
  • 35
    Lee WR, Berkey B, Marcial V, Fu KK, Cooper JS, Vikram B, et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys 1998; 42: 106975.
  • 36
    Dubray B, Mosseri V, Brunin F, Jaulerry C, Poncet P, Rodriguez J, et al. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology 1996; 201: 5538.
  • 37
    Fazekas JT, Scott C, Marcial V, Davis LW, Wasserman T, Cooper JS. The role of hemoglobin concentration in the outcome of misonidazole-sensitized radiotherapy of head and neck cancers: based on RTOG trial 79-15. Int J Radiat Oncol Biol Phys 1989; 17(6): 117781.
  • 38
    Canaday DJ, Regine WF, Mohiuddin M, Zollinger W, Machtay M, Lee J, et al. Significance of pretreatment hemoglobin level in patients with T1 glottic cancer. Radiat Oncol Invest 1999; 7: 428.
  • 39
    Overgaard J, Hansen HS, Jorgensen K, Hansen MH. Primary radiotherapy of larynx and pharynx carcinoma- an analysis of some factors influencing local control and survival. Int J Radiat Oncol Biol Phys 1986; 12(4): 51521.
  • 40
    Fein DA, Lee WR, Hanlon AL, Ridge JA, Langer CJ, Curran WJ, et al. Pretreatment hemoglobin level influences local control and survival of T1–T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 1995, 13(8): 207783.
  • 41
    Stadler P, Becker A, Feldmann HJ, Hansgen G, Dunst J, Wurschmidt F, et al. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 1999; 44(4); 74954.
  • 42
    San Miguel JF, Sanchez J, Gonzalez M. Prognostic factors and classification in multiple myeloma. Br J Cancer 1989; 59: 1138.
  • 43
    Hannisdal E, Kildahl-Andersen O, Grottum KA, Lamvik J. Prognostic factors in multiple myeloma in a population-based trial. Eur J Haematol 1990; 45: 198202.
  • 44
    Medical Research Council's Working Party on Leukaemia in Adults. Prognostic features in the third MRC myelomatosis trial. Br J Cancer 1980; 42: 83140.
  • 45
    Alexanian R, Balcerzak S, Bonnet JD, Gehan EA, Haut A, Hewlett JS, et al. Prognostic factors in multiple myeloma in a population-based trial. Cancer 1975; 36: 1192201.
  • 46
    Matzner Y, Benbassat J, Polliack A. Prognostic factors in multiple myeloma. Acta Haematol 1978; 60: 25768.
  • 47
    Carbone PP, Kellerhouse LE, Gehan EA. Plasmacytic myeloma. Am J Med 1967; 42: 93748.
  • 48
    Dunphy EP, Petersen LA, Cox RS, Bagshaw MA. The influence of initial hemoglobin and blood pressure levels on results of radiation therapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1988; 16: 11738.
  • 49
    Hussain M, Wolf M, Marshall E, Crawford ED, Eisenberger M. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in Phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol 1994; 12(9): 186875.
  • 50
    Mulders PF, Dijkman GA, Fernandez del Moral P, Theeuwes AGM, Debruyne FMJ, and Members of the Dutch Southeastern Urological Cooperative Group. Analysis of prognostic factors in disseminated prostatic cancer. An update. Dutch Southeastern Urological Cooperative Group. Cancer 1990; 65(12): 275861.
  • 51
    Emrich LJ, Priore RL, Murphy GP, Brady MF, and Investigators of the National Prostatic Cancer Project. Prognostic factors in patients with advanced prostate cancer. Cancer Res 1985; 45: 51739.
  • 52
    Smith DC, Dunn RL, Strawderman MS, Pienta KJ. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 1998; 16: 183543.
  • 53
    Sridhara R, Eisenberger MA, Sinibaldi VJ, Reyno LM, Egorin MJ. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol 1995; 13: 294453.
  • 54
    Vigario G, Kurohara SS, George FW. Association of hemoglobin levels before and during radiotherapy with prognosis in uterine cervix cancer. Radiology 1973; 106: 64952.
  • 55
    Schreiner P, Siracka E, Siracky J, Manka I. The effect of anemia on the radiotherapy results of the uterine cervix cancer. Neoplasma 1975; 22: 65560.
  • 56
    Solberger O, Sorbe B. Fever, haemoglobin and smoking as prognostic factors during the treatment of cervical carcinoma by radiotherapy. Eur J Gynaecol Oncol 1990; 11: 97102.
  • 57
    Thomson JM, Spratt JS Jr. Factors affecting survival in over 500 patients with Stage II carcinoma of the cervix. Radiology 1977; 123: 1813.
  • 58
    French Cooperative Group on Chronic Lymphocytic Leukaemia. Natural history of Stage A chronic lymphocytic leukaemia untreated patients. Br J Haematol 1990; 76: 4557.
  • 59
    Cervantes F, Rozman C. A multivariate analysis of prognostic factors in chronic myeloid leukemia. Blood 1982; 60: 1298304.
  • 60
    Kantarjian HM, Smith TL, McCredie KB, Keating MJ, Walters RS, Talpaz M, et al. Chronic myelogenous leukemia. Blood 1985; 66: 132635.
  • 61
    Advani SH, Rao DN, Gopal R, Nair CN, Battacharya M. Acute lymphoblastic leukemia end results analysis of treatment and prognostic factors in Indian patients. Am J Hematol 1983; 15: 3543.
  • 62
    Moullet I, Salles G, Ketterer N, Dumontet C, Bouafia F, Neidhart-Berard EM, et al. Frequency and significance of anemia in non-Hodgkin's lymphoma patients. Ann Oncol 1998; 9: 110915.
  • 63
    Fischer RI, Rubbard SM, DeVita VT. Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. Blood 1981; 58: 4551.
  • 64
    Straus DJ, Gaynor JJ, Myers J, Merke DP, Caravelli J, Chapman D, et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease with alternating potentially non-cross resistant chemotherapy and intermediate dose radiation therapy. J Clin Oncol 1990; 8: 117386.
  • 65
    Citterio G, Bertuzzi A, Tresoldi M, Galli L, Di Lucca G, Scaglietti U, et al. Prognostic factors for survival in metastatic renal cell carcinoma: retrospective analysis from 109 consecutive patients. Eur Urol 1997; 31(3): 28691.
  • 66
    Lund B, Williamson P. Prognostic factors for overall survival in patients with advanced ovarian carcinoma. Ann Oncol 1991; 2(4): 2817.
  • 67
    Graf W, Glimelius B, Pahlman L, Bergstrom R. Determinants of prognosis in advanced colorectal cancer. Eur J Cancer 1991; 27(9): 111923.
  • 68
    Edler L, Heim ME, Quintero C, Brummer T, Queisser W. Prognostic factors of advanced colorectal cancer patients. Eur J Cancer Clin Oncol 1986; 22: 12317.
  • 69
    Su CH, Shyr YM, Lui WY, P'eng FK. Factors affecting morbidity, mortality and survival after pancreaticoduodenectomy for carcinoma of the ampulla of Vater. Hepatogastroenterology 1999; 46: 19739.
  • 70
    Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113(3): 72331.
  • 71
    Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; 17(10): 317381.
  • 72
    Reed WR, Hussey DH, DeGowin RL. Implications of the anaemia of chronic disorders in patients anticipating radiotherapy. Am J Med Sci 1994; 308(1): 915.